176 related articles for article (PubMed ID: 24136145)
21. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
22. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
23. Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.
Eshagh K; Romero LS; So JK; Zhao XF
Cutis; 2017 Feb; 99(2):E30-E34. PubMed ID: 28319634
[TBL] [Abstract][Full Text] [Related]
24. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
26. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
27. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
[TBL] [Abstract][Full Text] [Related]
29. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
30. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
31. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.
Pellegrini C; Stefoni V; Casadei B; Maglie R; Argnani L; Zinzani PL
Ann Hematol; 2014 Nov; 93(11):1853-7. PubMed ID: 24908331
[TBL] [Abstract][Full Text] [Related]
34. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
35. Combination treatment in CTCL: the current role of bexarotene.
Delfino C; Grandi V; Pileri A; Rupoli S; Quaglino P; Alterini R; Goteri G; Canafoglia L; Pimpinelli N
G Ital Dermatol Venereol; 2012 Dec; 147(6):573-80. PubMed ID: 23149703
[TBL] [Abstract][Full Text] [Related]
36. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
37. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
38. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
39. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]